Sol-Gel Technologies Ltd. (SLGL): Operating Cash Flow
$322.0K
Year ended 2025-12-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $322.0K | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | -$13.89M | n/m | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | -$17.73M | n/m | 2026-03-19, From 2023-01-01 |
| 2022-12-31 | -$9.48M | n/m | 2025-04-29, From 2022-01-01 |
| 2021-12-31 | -$7.69M | n/m | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | -$25.24M | n/m | 2023-03-10, From 2020-01-01 |
| 2019-12-31 | -$22.50M | n/m | 2022-04-07, From 2019-01-01 |
| 2018-12-31 | -$23.47M | n/m | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | -$24.09M | n/m | 2020-03-24, From 2017-01-01 |
| 2016-12-31 | -$18.50M | n/m | 2019-03-21, From 2016-01-01 |
| 2015-12-31 | -$8.04M | n/a | 2018-03-26, From 2015-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $322.0K | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$1.99M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | -$5.28M | n/m |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$20.75M | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | -$147.78M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | -$177.96M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | -$369.52M | n/m |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | -$128.51M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$35.25M | n/m |
Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗